Early Treatment Of Multiple Sclerosis; Gd+: Gadolinium-enhancing; IM: Intramuscular; NA: Not applicable; PreCISe: Effect of Glatiramer Acetate Treatment in Delaying Conversion to Clinically ...

The molecular mechanisms underlying myelin sheath destruction in multiple sclerosis lesions remain unresolved. With immunogold–labeled peptides of myelin antigens and high–resolution ...

The objective of this investigation was to examine treatment persistence with glatiramer acetate (GA) relative to available disease-modifying therapies (DMT) for multiple sclerosis (MS ...

Fenebrutinib showed an annualized relapse rate of 0.06 and no disability progression at 96 weeks. T2 lesion rate fell from 6.72 to 0.34 after switching to fenebrutinib in the open-label extension.

Presenting Author: Dr. John Foley – Rocky Mountain Multiple Sclerosis, Salt Lake City, Utah Following the presentations, the data presented will be available on the Publications page ...

As a whole, disease-modifying therapies (DMTs) for multiple sclerosis (MS ... They added that “glatiramer acetate and dimethyl fumarate appear to lower the risk of stroke” while “concerns ...

aQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK bMedical Research ...

Canada xMultiple Sclerosis Centre of Catalonia, Department of Neurology–Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain ySection of ...

Summary: A new study reveals that acetate, when paired with specific gut bacteria, can significantly reduce fat and liver mass in both normal and obese mice. Researchers used a supplement called ...